Kaitlyn McIntosh
Payments from drug & device makers
Across 87 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$307
- AstraZeneca$280
- AbbVie$208
- Otsuka America Pharmaceutical, Inc.$144
- Lundbeck LLC$87
- GSK$79
- plus $511 from 16 others
What the payments were for
- Food & beverage$1,615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $307 |
| AstraZeneca | 14 | $280 |
| AbbVie | 12 | $208 |
| Otsuka America Pharmaceutical, Inc. | 7 | $144 |
| Lundbeck LLC | 3 | $87 |
| GSK | 5 | $79 |
| Exact Sciences | 3 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Bayer | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $39 |
| Alkermes, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $34 |
| Corium, LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Bioventus LLC | 1 | $15 |
| Amgen | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
How this compares
$1,615 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $32,356 |
| JardianceEmpagliflozin | 33 | $24,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,966 |
| OzempicSemaglutide | 11 | $13,738 |
| TrulicityDulaglutide | 12 | $11,396 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,105 |
| FarxigaDapagliflozin Propanediol | 13 | $8,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,351 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $2,173 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,173 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 11 | $973 |
| Ventolin HfaAlbuterol Sulfate | 15 | $898 |
| Atorvastatin Calcium | 90 | $879 |
| Duloxetine Hcl | 30 | $858 |
| Omeprazole | 56 | $830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $32,35635 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $79 | $28,07136 claims |
| Boehringer IngelheimJardiance | $21 | $24,20633 claims |
| Novo NordiskOzempic | $307 | $13,73811 claims |
| Lilly USA, LLCTrulicity | $34 | $11,39612 claims |
| AstraZenecaFarxiga | $280 | $8,35513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,657 family providers in Michigan.
Other family in Caro
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.